Since BRAFV600E can suppress the activity of the MITF-PGC1α axis, which is followed by diminished OXPHOS in melanoma [72], BRAFi/MEKi can induce a metabolic switch by promoting OXPHOS in melanoma cells, which may also increase melanoma cell vulnerability to copper ionophores and copper-containing nanodrugs (Fig. 4). This evidence concerns the gene PPARGC1A and melanoma.